AcroCyte Therapeutics Secures ARPA‑H Funding to Scale Human Organoid Technologies

0
74

Key Takeaways

  • AcroCyte Therapeutics has been awarded ARPA‑H funding to advance scalable human organoid technologies for regenerative medicine.
  • The company’s proprietary R3CE® platform enables standardized, reproducible 3‑D expansion of rare human cells and is the first FDA‑registered Class I medical device for organoid production.
  • The funded project will pursue a binational strategy, collaborating with the University of Chicago Medicine (U.S.) and National Taiwan University Hospital (NTUH) alongside the National Center for Biomodels.
  • Leadership statements highlight the award as validation of AcroCyte’s technology and its potential to address global organ shortages, especially for kidney disease.
  • AcroCyte’s mission centers on creating animal‑free, high‑throughput organoid models for drug discovery, safety assessment, and translational regenerative medicine.

ARPA‑H Funding Announcement
On July 23, 2026, AcroCyte Therapeutics Inc. revealed that it has been selected to receive funding from the Advanced Research Projects Agency for Health (ARPA‑H). The announcement was made during a press conference held in Taipei, Taiwan. ARPA‑H, established by the U.S. government in 2022, mirrors the model of the Defense Advanced Research Projects Agency (DARPA) and is tasked with supporting high‑risk, high‑reward research capable of transforming human health. Rather than financing incremental improvements, ARPA‑H seeks to catalyze disruptive technologies that can solve major unmet medical and societal challenges. AcroCyte’s selection underscores the agency’s confidence in the company’s ability to deliver breakthrough organoid solutions.

ARPA‑H’s Focus on Regenerative Medicine
Among ARPA‑H’s priority areas, regenerative medicine stands out, particularly initiatives aimed at alleviating the global shortage of transplantable organs. The agency backs programs that develop bioengineered, clinically functional replacement tissues and organs. By funding AcroCyte, ARPA‑H recognizes the startup’s original cell expansion technology as a critical enabler for these ambitious goals. The award is expected to accelerate the translation of organoid research from laboratory proof‑of‑concept to scalable, clinically relevant products.

Core Technology: The R3CE® Platform
AcroCyte’s breakthrough lies in its proprietary R3CE® (Rapid Reproducible Rare Cell 3D Expansion) platform, which addresses long‑standing obstacles in organoid development such as scalability, reproducibility, and manufacturing standardization. The R3CE® system enables highly reproducible, three‑dimensional expansion of rare human cells under defined conditions. Notably, the platform has earned FDA registration as a Class I medical device, marking it as the first standardized organoid expansion system to achieve this regulatory designation. This status facilitates smoother pathways toward clinical adoption and commercialization.

From Patient Cells to Renal Organoids
Using minimally invasive procedures, autologous kidney cells can be harvested from patients and expanded within weeks into physiologically relevant renal organoid modules via the R3CE® platform. This capability opens new avenues for regenerative research and translational development that go beyond traditional organ transplantation. Patient‑specific organoids hold promise for disease modeling, drug testing, and ultimately, autologous tissue repair, reducing reliance on donor organs and minimizing immunogenic complications.

International Clinical Strategy: U.S.–Taiwan Collaboration
The ARPA‑H‑supported project will be executed through a binational clinical and translational strategy, linking expertise in the United States and Taiwan. AcroCyte will partner with the University of Chicago Medicine in the U.S. and National Taiwan University Hospital (NTUH), together with the National Center for Biomodels (NCB), to pursue parallel development efforts across both regions. This coordinated approach aims to align early with international regulatory standards, streamline data sharing, and accelerate the path toward global clinical applications. By leveraging complementary strengths—U.S. leadership in clinical trials and Taiwan’s robust biomedical infrastructure—the project seeks to maximize impact and efficiency.

CEO’s Perspective on the CEO, Dr. Ying C. Chang
Dr. Ying C. Chang, Co‑Founder and Chief Executive Officer of AcroCyte Therapeutics, expressed enthusiasm about the ARPA‑H endorsement. “Being selected for support by ARPA‑H is a strong validation of our team’s long‑term commitment to advancing three‑dimensional cell technologies,” Chang said. He noted that the award follows AcroCyte’s recognition at MEDICA 2025, where the company became the first Taiwanese biotech firm to secure second place in the MEDICA Start‑up Competition. Chang emphasized that the milestone underscores AcroCyte’s role in advancing organoid technologies across borders and reiterated the company’s focus on translating organoid platforms from the lab into standardized systems that support regenerative and translational medicine.

NTUH’s Viewpoint from Vice Superintendent Professor Jia‑Horng Kao
Professor Jia‑Horng Kao, Vice Superintendent of National Taiwan University Hospital, highlighted the significance of NTUH’s participation as a clinical partner alongside the University of Chicago Medicine. “NTUH participation as a clinical partner alongside the University of Chicago Medicine in this ARPA‑H project reflects international recognition of our clinical and research excellence in regenerative medicine,” Kao stated. He pointed out that kidney disease remains a major health concern in Taiwan and expressed hope that integrating global research resources and clinical expertise will advance regenerative medicine solutions for patients suffering from chronic kidney disease.

About AcroCyte Therapeutics Inc.
AcroCyte Therapeutics Inc. is a biotechnology company dedicated to tackling key challenges in New Approach Methodologies (NAMs) by enabling reproducible, robust, and scalable human‑relevant model systems. Through its organoid platforms, the firm advances animal‑free, high‑throughput alternatives for drug discovery and safety assessment while enhancing translational relevance across drug development and regenerative medicine. The company maintains research and development operations in Silicon Valley, California, and continues to refine high‑quality, scalable cell‑based technologies aimed at global clinical use. AcroCyte’s work is positioned to bridge the gap between basic scientific discovery and practical therapeutic applications.

Funding Disclosure and Note
The research described in this announcement received partial funding from the Advanced Research Projects Agency for Health (ARPA‑H). The views and conclusions presented are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the U.S. Government. This clarification ensures transparency regarding the source of support while affirming AcroCyte’s responsibility for the scientific content and interpretations shared.

SignUpSignUp form

LEAVE A REPLY

Please enter your comment!
Please enter your name here